A post-hoc subgroup analysis of ONTARGET® showed no increase in the risk of stroke, other major CV or renal outcomes in patients with diabetes with or without nephropathy [102], unlike the ALTITUDE trial results which suggested that use of aliskiren in combination with an ACE inhibitor or an ARB increased risk of stroke in people with diabetes [100]. The gene discussed is ACE; the disease is stroke disorder.